Sunil Healthcare FY26 consolidated profit rises, standalone loss reported

2 min read     Updated on 31 May 2026, 02:56 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Sunil Healthcare Limited reported a consolidated net profit of ₹400.60 lakh for FY26, against a consolidated loss of ₹141.66 lakh in the previous year, while standalone results reflected a net loss of ₹530.21 lakh. The standalone loss was driven by exceptional items of ₹958.25 lakh, including a ₹946.66 lakh provision for a foreign subsidiary and a ₹355.95 lakh write-off for a fire incident at the Alwar plant. The Board approved the audited results on May 29, 2026, and the company published the financial results in newspapers on May 31, 2026.

powered bylight_fuzz_icon
41630080

*this image is generated using AI for illustrative purposes only.

Sunil Healthcare Limited reported a consolidated net profit of ₹400.60 lakh for the financial year ended March 31, 2026, while its standalone results reflected a net loss of ₹530.21 lakh. The standalone performance was significantly impacted by exceptional items amounting to ₹958.25 lakh, primarily due to a provision for a foreign subsidiary and a fire incident at its Alwar plant. The company published the audited financial results for the quarter and year ended March 31, 2026, in the newspaper Pioneer on May 31, 2026, pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company's consolidated revenue from operations for FY26 stood at ₹8,990.15 lakh, compared to ₹8,476.02 lakh in the previous year. On a standalone basis, revenue increased to ₹8,886.23 lakh from ₹8,477.28 lakh in FY25. The statutory auditors, M/s. Singhi & Co., Chartered Accountants, issued an unmodified opinion on the annual standalone and consolidated financial results.

Financial Performance

The divergence between standalone and consolidated profitability was driven by exceptional items recorded during the quarter ended March 31, 2026. The company reassessed the recoverability of outstanding balances from a foreign subsidiary, leading to a provision of ₹946.66 lakh. Additionally, a fire incident at the Alwar manufacturing plant resulted in damage to property, plant, and equipment with a carrying value of ₹355.95 lakh, which was written off. The company has recognized an insurance claim receivable of ₹344.35 lakh, expecting the loss to be fully recoverable.

Metric Standalone FY26 (₹ in Lakhs) Standalone FY25 (₹ in Lakhs) Consolidated FY26 (₹ in Lakhs) Consolidated FY25 (₹ in Lakhs)
Revenue from Operations 8,886.23 8,477.28 8,990.15 8,476.02
Total Income 8,886.23 8,477.28 8,990.15 8,476.02
Total Expenses 8,635.79 8,436.68 8,755.56 8,597.59
Profit/(Loss) for the period (530.21) 20.51 400.60 (141.66)

Board Decisions

The Board of Directors met on May 29, 2026, to discuss the financial outcomes. In addition to approving the audited financial results, the Board appointed M/s. Agrawal S. Lal & Co., Chartered Accountants, as internal auditors for the financial year 2026-27. The Board also approved the Directors' Report for FY26.

The company's total assets as of March 31, 2026, stood at ₹16,232.00 lakh on a standalone basis and ₹16,450.55 lakh on a consolidated basis. The cash and cash equivalents at the end of the year were ₹6.53 lakh for the standalone entity and ₹7.39 lakh for the consolidated entity.

Historical Stock Returns for Sunil Healthcare

1 Day5 Days1 Month6 Months1 Year5 Years
-5.97%-3.05%-1.87%-13.07%-14.22%+98.74%

What is the expected timeline for the settlement of the ₹344.35 lakh insurance claim regarding the Alwar plant fire?

How does the company plan to address the recoverability issues with the foreign subsidiary to prevent future provisions?

Will the fire incident at the Alwar plant impact production capacity or revenue growth in the upcoming fiscal year?

Sunil Healthcare Schedules Board Meeting on May 29, 2026 to Approve Q4 and FY 2025-26 Audited Financial Results

1 min read     Updated on 19 May 2026, 03:08 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Sunil Healthcare Limited has informed stock exchanges of a Board of Directors meeting to be held on May 29, 2026, via video conferencing, to consider and approve audited standalone and consolidated financial results for Q4 and the full financial year 2025-26 ended March 31, 2026. The meeting is being convened in compliance with Regulation 29 read with Regulation 33 of the SEBI (LODR) Regulations, 2015. The company has also confirmed that the Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015, remains closed from April 01, 2026 to May 31, 2026, both days inclusive, as previously intimated on March 27, 2026.

powered bylight_fuzz_icon
40729082

*this image is generated using AI for illustrative purposes only.

Sunil Healthcare Limited has notified the stock exchanges of an upcoming Board of Directors meeting scheduled for Friday, May 29, 2026. The meeting will be conducted through video conferencing/audio visual connection, with the deemed venue being the company's registered office at 38E/252A, Vijay Tower, 3rd Floor, Panchsheel Commercial Complex, Shahpur Jat, New Delhi-110049.

Board Meeting to Consider Audited Financial Results

The board meeting has been convened pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary agenda of the meeting is to consider, approve, and take on record the audited financial results of the company for the period detailed below.

Parameter: Details
Meeting Date: Friday, May 29, 2026
Meeting Mode: Video Conferencing / Audio Visual Connection
Deemed Venue: 38E/252A, Vijay Tower, 3rd Floor, Panchsheel Commercial Complex, Shahpur Jat, New Delhi-110049
Results to be Considered: Audited Financial Results (Standalone & Consolidated)
Period Under Review: Q4 FY 2025-26 and Full Year FY 2025-26
Financial Year End Date: March 31, 2026
Regulatory Framework: Regulation 29 read with Regulation 33, SEBI (LODR) Regulations, 2015

Trading Window Closure

In accordance with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company has confirmed that the Trading Window remains closed. This closure was previously intimated to the exchanges vide the company's letter dated March 27, 2026.

Parameter: Details
Trading Window Closure Start: April 01, 2026
Trading Window Closure End: May 31, 2026
Both Days: Inclusive

The intimation was signed by Satyendu Pattnaik, Company Secretary & Compliance Officer (M.No. F7736), on behalf of Sunil Healthcare Limited, and was dated May 19, 2026.

Historical Stock Returns for Sunil Healthcare

1 Day5 Days1 Month6 Months1 Year5 Years
-5.97%-3.05%-1.87%-13.07%-14.22%+98.74%

How might Sunil Healthcare's FY 2025-26 full-year financial results compare to industry peers in the pharmaceutical sector, and what growth trajectory could they signal for FY 2026-27?

Will the board meeting on May 29 include any announcements beyond financial results, such as dividend declarations, capital raising plans, or strategic expansions?

How could the audited consolidated results differ from standalone figures, and what subsidiaries or associates might significantly impact the consolidated performance?

More News on Sunil Healthcare

1 Year Returns:-14.22%